Onvansertib
- Generic Name
- Onvansertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F3N8O3
- CAS Number
- 1034616-18-6
- Unique Ingredient Identifier
- 67RM91WDHQ
- Background
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT06736717
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT06398587
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 90
- Registration Number
- NCT06106308
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 23
- Registration Number
- NCT05593328
- Locations
- 🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Washington University School of Medicine Center for Advanced Medicine, Saint Louis, Missouri, United States
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT05549661
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Taofeek Owonikoko
- Target Recruit Count
- 37
- Registration Number
- NCT05450965
- Locations
- 🇺🇸
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Onvansertib + Paclitaxel In TNBC
- Conditions
- Hormone Receptor/Growth Factor Receptor-Negative Breast CancerHER2-negative Breast CancerHormone Receptor Negative Breast CarcinomaBreast CancerUnresectable Breast CarcinomaLocally Advanced Breast CancerMetastatic Breast CancerInvasive Breast CancerTriple Negative Breast Cancer (TNBC)Inflammatory Breast Cancer
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Antonio Giordano, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05383196
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 43
- Registration Number
- NCT04752696
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Cardiff Oncology
- Registration Number
- NCT04446793
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT04005690
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.